Cargando…

Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial

The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meister, Toni Luise, Gottsauner, Josef-Maximilian, Schmidt, Barbara, Heinen, Natalie, Todt, Daniel, Audebert, Franz, Buder, Felix, Lang, Henriette, Gessner, André, Steinmann, Eike, Vielsmeier, Veronika, Pfaender, Stephanie, Cieplik, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057949/
https://www.ncbi.nlm.nih.gov/pubmed/35504446
http://dx.doi.org/10.1016/j.virusres.2022.198791
_version_ 1784698014753882112
author Meister, Toni Luise
Gottsauner, Josef-Maximilian
Schmidt, Barbara
Heinen, Natalie
Todt, Daniel
Audebert, Franz
Buder, Felix
Lang, Henriette
Gessner, André
Steinmann, Eike
Vielsmeier, Veronika
Pfaender, Stephanie
Cieplik, Fabian
author_facet Meister, Toni Luise
Gottsauner, Josef-Maximilian
Schmidt, Barbara
Heinen, Natalie
Todt, Daniel
Audebert, Franz
Buder, Felix
Lang, Henriette
Gessner, André
Steinmann, Eike
Vielsmeier, Veronika
Pfaender, Stephanie
Cieplik, Fabian
author_sort Meister, Toni Luise
collection PubMed
description The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies.
format Online
Article
Text
id pubmed-9057949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-90579492022-05-02 Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial Meister, Toni Luise Gottsauner, Josef-Maximilian Schmidt, Barbara Heinen, Natalie Todt, Daniel Audebert, Franz Buder, Felix Lang, Henriette Gessner, André Steinmann, Eike Vielsmeier, Veronika Pfaender, Stephanie Cieplik, Fabian Virus Res Article The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies. The Author(s). Published by Elsevier B.V. 2022-07-15 2022-05-02 /pmc/articles/PMC9057949/ /pubmed/35504446 http://dx.doi.org/10.1016/j.virusres.2022.198791 Text en © 2022 The Author(s). Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Meister, Toni Luise
Gottsauner, Josef-Maximilian
Schmidt, Barbara
Heinen, Natalie
Todt, Daniel
Audebert, Franz
Buder, Felix
Lang, Henriette
Gessner, André
Steinmann, Eike
Vielsmeier, Veronika
Pfaender, Stephanie
Cieplik, Fabian
Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title_full Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title_fullStr Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title_full_unstemmed Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title_short Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
title_sort mouthrinses against sars-cov-2 – high antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057949/
https://www.ncbi.nlm.nih.gov/pubmed/35504446
http://dx.doi.org/10.1016/j.virusres.2022.198791
work_keys_str_mv AT meistertoniluise mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT gottsaunerjosefmaximilian mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT schmidtbarbara mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT heinennatalie mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT todtdaniel mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT audebertfranz mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT buderfelix mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT langhenriette mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT gessnerandre mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT steinmanneike mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT vielsmeierveronika mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT pfaenderstephanie mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial
AT cieplikfabian mouthrinsesagainstsarscov2highantiviraleffectivitybymembranedisruptioninvitrotranslatestomildeffectsinarandomizedplacebocontrolledclinicaltrial